News
Long-term erythromycin reduces COPD exacerbations in study
Posted: Friday November 21, 2008 under News Announcements
Newswise
Long-term use of a macrolide antibiotic may reduce the frequency of exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD) by as much as 35 percent, according to a London-based study.
COPD Awareness campaign comes to Facebook
Posted: Thursday November 20, 2008 under News Announcements
Throughout COPD Awareness Month, the National Heart, Lung & Blood Institute’s “Learn More Breathe Better” campaign spread the word about COPD through all the conventional media—newspapers, TV, radio—and also by social media outreach, from blogging to e-cards to widgets.—and Facebook.
It's annual open enrollment time for Medicare drug plans
Posted: Thursday November 20, 2008 under News Announcements
Naples Daily News
Homework time has rolled around again for anyone on a Medicare drug plan.
Foundation, Talecris announce two research grant awards
Posted: Tuesday November 18, 2008 under News Press Releases
Researchers to develop line of Alpha-1 mice, map structure of AAT polymers
RESEARCH TRIANGLE PARK, NC and MIAMI, FL — The Alpha-1 Foundation has awarded two new research grants for projects at the University of Florida and Brandeis University. The grants were made possible through an unrestricted charitable donation from Talecris Biotherapeutics to the Alpha-1 Foundation.
ATS annual conference May 15-20 in San Diego
Posted: Monday November 17, 2008 under News Announcements
SAN DIEGO, CA—The annual conference of the American Thoracic Society (ATS) will be held in San Diego May 15-20, 2009. The conference will feature more than 400 sessions on the diagnosis and treatment of respiratory, critical care and sleep disorders.
Memorial service scheduled for Dr. David Pogue, TX Alpha
Posted: Friday November 14, 2008 under News Announcements
TimesRecordNews, Wichita Falls, TX
Dr. David MacCharles Pogue passed away Oct. 27 after a long struggle with lung disease caused by Alpha-1 antitrypsin deficiency.
NYC Alpha-1 Swim Team member's law firm receives "Pro Bono" Award
Posted: Thursday November 13, 2008 under News Announcements
Steven Reiss, a litigation partner at Weil Gotshal & Manges in New York and co-chairman of the firm’s pro bono practice, swam the English Channel last August to raise research funds and awareness for Alpha-1 antitrypsin deficiency, a rare genetic lung disease.
Survey finds growing awareness of COPD, nation’s 4th Leading killer
Posted: Thursday November 13, 2008 under News Press Releases
Understanding of the disease and its risk factors, including smoking, remains low
WASHINGTON—Awareness of COPD (chronic obstructive pulmonary disease) is growing, but few Americans have a thorough understanding of the disease, according to a national survey released today. The new data show that 64 percent of survey respondents have heard of COPD, compared with 49 percent in a 2004 survey. Among those who reported hearing of COPD, only half recognized the disease as a leading cause of death, and just 44 percent understood it to be treatable.
French biotech firm invests in GTC, developer of recombinant AAT
Posted: Wednesday November 12, 2008 under News Announcements
Mass Hi Tech, The Journal of New England Technology
Transgenic therapeutics company GTC Biotherapeutics Inc. and French firm LFB Biotechnologies, a wholly owned subsidiary of LFB S.A., have entered an agreement in which LFB will purchase $15 million worth of GTC common stock and convertible debt, subject to GTC shareholder approval. Closing of the transaction and shareholder voting will take place in December, and GTC said it expects about $10 million in net proceeds.
Kamada signs long-term supply agreement for AAT raw material
Posted: Tuesday November 11, 2008 under News Press Releases
NESS ZIONA, Israel—Kamada, a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has signed a long-term supply agreement with a multi-national company for the raw material required to manufacture AAT (alpha-1 antitrypsin), Kamada’s flagship product, which is administered intravenously or by inhalation.
